**Docetaxel**

**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.1. Cytotoxic medicines

**Indication**: Malignant neoplasms of prostate  
**ICD11 code**: 2D32.Z

**INN**: Docetaxel  
**Medicine type**: Chemical agent  
**List type**: Complementary

**Formulations**: Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

**EML status history**:  
First added in 2011 (TRS 965)  
Changed in 2015 (TRS 994)

**Sex**: All

**Age**: Adolescents and adults

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Tags**: Cancer

**Wikipedia**: Docetaxel

**DrugBank**: Docetaxel

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for docetaxel on the complementary list of the EML for use in treatment protocols for metastatic prostate cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.

[Expert Committee report]